Master in Vaccinology and Drug Development

01/12/2025

🎥 Today we share this World Health Organization (WHO) video for World AIDS Day.

This reminder from highlights a powerful milestone in the HIV response: Lenacapavir, a twice-yearly long-acting drug that represents a major breakthrough in prevention and treatment.

Innovations like this can help close gaps in access, improve adherence, and bring life-changing options to communities most affected by HIV.

On December 1, we honor the progress made and acknowledge the work that remains.

Ending AIDS is possible—when science, equity, and human rights move forward together
Everyone deserves the chance to live healthy, supported, and stigma-free.

https://www.youtube.com/watch?v=rKX2JrqR_o0

Have you heard about Lenacapavir or LEN, a new drug WHO recommends to protect people at risk of HIV? For some people, taking daily pills is not easy. But Len...

01/12/2025

🌍 World AIDS Day

Today we honor the global fight against HIV/AIDS, remembering the millions of lives impacted and recognizing the ongoing work of scientists, healthcare professionals, and communities worldwide.

✨ Together, we move closer to a future without HIV/AIDS.

🔬 Education. Innovation. Impact.
ifgh.org

28/11/2025

🎓 Advancing Global Health Through Expertise.

The Master in Vaccinology and Drug Development prepares professionals to design, assess, and implement life-saving vaccines and therapeutics for populations worldwide.

👏With more than ten years of academic excellence, over 99% of graduates remain active in vaccinology or public health within five years — driving initiatives that reinforce global health systems and improve lives. 🌍💉

Learn more: ifgh.org

26/11/2025

🤝 Our Gratitude to the Sponsors

The Master in Vaccinology and Drug Development thrives thanks to the invaluable support of our sponsors. Your ongoing commitment helps us strengthen capabilities, train the next generation of vaccine experts, and advance global health—particularly in low- and middle-income countries.

Because of your support, our alumni are leading vaccine trials, reinforcing health systems, and creating meaningful impact in their communities across the globe.

🌍 Together, we’re building a healthier future.

▪️Gates Foundation
▪️Novartis
▪️Sanofi
▪️Takeda
▪️Valneva
▪️CureVac
▪️Grid Europe
▪️VisMederi Group
▪️CEPI
▪️VaxTrials
▪️Cevaxin
▪️Fundação Lemann
▪️Syneos Health
▪️International Vaccine Institute
▪️Clover Biopharmaceuticals
▪️University of Wisconsin-Madison Global Health Institute
▪️Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)
▪️Arcturus Therapeutics

Co-managing entity: Fondazione Vismeredi

🌐 www.ifgh.org

25/11/2025

🌍 Building the future of global health, one expert at a time.

The Master in Vaccinology and Drug Development shapes professionals who drive progress in vaccine research, policy, and implementation across the world.

For more than a decade, our graduates have taken leadership roles in organizations that transform scientific discovery into life-saving solutions. 💉🎓

Join a community committed to advancing public health — where innovation meets impact.

Learn more: ifgh.org

20/11/2025

🔬 Reevaluating adult RSV infections: a call for action

A recent comparative study reveals that the burden of Respiratory Syncytial Virus infection (RSV) in adults – especially those aged 60 and over – is comparable to that of influenza.

With almost 60 % of RSV cases requiring hospitalization and a high need for oxygen therapy, this research underscores the urgent need to accelerate vaccine and treatment developments for adults.

➡️ Read the full study here: https://pubmed.ncbi.nlm.nih.gov/40302540/

Respiratory Syncytial Virus (RSV) is well known for its impact on children, but its burden in adults remains underexplored, partly due to limited PCR testing before the COVID-19 pandemic. In this study, the medical burden of RSV infections in adults was retrospectively investigated using 6-year long...

18/11/2025

🎓 Driving Global Health Impact

The Master in Vaccinology and Drug Development equips professionals with the skills to design, evaluate, and implement vaccines and treatments that save lives worldwide.

With over a decade of excellence, more than 99% of graduates continue working in vaccinology or public health within five years of completing the program — leading initiatives that strengthen global health systems. 🌍💉

Be part of this global network of innovators and changemakers.
Learn more: ifgh.org

14/11/2025

💙 World Diabetes Day reminds us of the growing impact of this global health challenge — and the vital role of innovation in prevention and treatment.

Through continuous research in vaccinology and drug development, scientists and health professionals are shaping solutions that improve lives and strengthen public health systems worldwide. 🌍💉

At the Master in Vaccinology and Drug Development, we empower future leaders to drive this change.

Learn more: ifgh.org

12/11/2025

💙 Today we raise awareness for Pneumonia Awareness Day — a reminder that prevention saves lives.

Vaccines remain one of the most effective tools to protect people of all ages from pneumonia and its complications. Through continuous research, education, and innovation, we move closer to a world where no one dies from a preventable disease. 🌍💉

Learn more about how the Master in Vaccinology and Drug Development is shaping experts in global health and vaccine research: ifgh.org

10/11/2025

🌍 Shape the future of global health.

The Master in Vaccinology and Drug Development empowers professionals to innovate, lead, and make a real impact through vaccine and drug research. Gain the expertise to turn scientific knowledge into life-saving solutions. 💉🎓

Discover how: ifgh.org

07/11/2025

🔬 Advancing the frontier of infectious disease research

A new publication in The Lancet Infectious Diseases highlights the importance of targeted interventions to reduce the global burden of infectious diseases — reaffirming how research and innovation drive progress in public health.

🌍💉Read the full study here: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00455-9/abstract

Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved ...

06/11/2025

📲 Be part of our global community and stay up to date with the latest in vaccinology and drug development!

Follow us and connect with experts, students, and professionals around the world:
🔹 Instagram: https://www.instagram.com/master.in.vaccinology

🔹 LinkedIn: https://www.linkedin.com/company/master-in-vaccinology-and-drug-development

🔹 X (Twitter): https://x.com/InVaccinology

🔹 Facebook: https://www.facebook.com/vaccinology.drug.development

🌐 Learn more at www.ifgh.org